
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is viewed positively because its vertically integrated platform combines FDA-cleared connected devices, proprietary AI, and coaching to address high-prevalence chronic conditions like diabetes, obesity, MSK, behavioral health, and sleep, creating a differentiated one-stop shop for employers and health plans. Its commercial traction appears meaningful, with 180+ clients, roughly 25% Fortune 500, access to more than 175M lives through plans and partnerships, and about 85 new clients added in 2025, while over 80% of ARR comes from multi-condition sales and 90% client retention supports visibility. Although 2025 and 1H:26 revenue declines reflect a planned shift away from bio-pharma and a legacy account loss, the company’s $13.1M of contracted new business and late-stage ARR, 62% gross margin in 2Q:26, and DarioIQ’s 13B+ data-point flywheel support improving revenue, margins, and cash flow.
Bears say
DarioHealth is facing a negative fundamental setup because it competes in a crowded digital health market for employers and payers, where differentiation on outcomes, pricing, and engagement is difficult and demand could shift toward other benefit categories. Revenue momentum also appears fragile: 2Q rev of $5.2M missed estimates, adj. EBITDA loss was $(5.3)M, and management has no official guidance, while $13M of new contracted ARR is not expected to begin ramping until 4Q and through 2027. Financial strain adds risk, with about $31M of debt versus ~$7M of cash in 2Q:26, and weaker digital health demand, churn, and potential dilutive capital raises could keep shares under pressure.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DarioHealth (DRIO) Forecast
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares